The combination of interleukin-2 (IL-2) agonism with programmed cell death protein 1 (PD-1) checkpoint inhibition has previously demonstrated synergistic efficacy in promoting antitumor T-cell responses. However, the incompatible dose levels and dosing schedules of the two therapeutic mechanisms have made their integration within a single molecule challenging.
Akari Therapeutics plc announced that it is continuing key research on its antibody-drug conjugate (ADC) payload PH1 to further demonstrate its ability to target cancers fueled by oncogenic drivers. PH1 is a spliceosome modulator designed to disrupt RNA splicing within cells. It binds spliceosome proteins SF3B1 and PH5α and targets normal splicing of pre-mRNA. PH1 is a spliceosome modulator designed to disrupt RNA splicing within cells. It binds spliceosome proteins SF3B1 and PH5α and targets normal splicing of pre-mRNA.
The sodium-dependent phosphate transport protein 2b (NaPi2b), encoded by the SLC34A2 gene, is highly overexpressed in high-grade epithelial ovarian cancer and non-small-cell lung cancer while exhibiting minimal expression in normal adult tissues, making it a relevant tumor-associated antigen and a promising target for antibody-drug conjugates (ADCs).
SML Biopharm Co. Ltd. is harnessing mRNA technology to develop novel immunotherapy-based cancer vaccines, including two candidates for cervical and head and neck cancers caused by human papillomavirus (HPV) infection.
There are a raft of problems the U.S. FDA wants resolved before Replimune Group Inc.’s BLA for RP-1 (vusolimogene oderparepvec) with nivolumab to treat advanced melanoma goes any further, all of which the company said are a surprise.
Colorectal cancer remains a prevalent and deadly form of cancer. A significant challenge to treating colorectal tumors is the creation of a suppressive tumor immune microenvironment that leads to tumor progression and resistance to immunotherapy.
Interleukin-18 (IL-18) is a pro-inflammatory cytokine that plays a crucial role in promoting antitumor immunity by activating T and natural killer (NK) cells. However, the therapeutic use of wild-type IL-18 has faced limitations due to its susceptibility to neutralization by IL-18 binding protein (IL-18BP), short in vivo half-life and unfavorable physicochemical properties.
SML Biopharm Co. Ltd. is harnessing mRNA technology to develop novel immunotherapy-based cancer vaccines, including two candidates for cervical and head and neck cancers caused by human papillomavirus (HPV) infection.
Lung cancer is the most frequent cause of cancer-related death in both men and women worldwide. Current treatments can fail because of variable responses in different types of patients, drug resistance, poor tumor penetration and systemic toxicity, prompting the continuing search for better therapeutics.
Genome Therapeutics Ltd. has synthesized compounds and their immunoconjugates comprising an antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
RSS
